European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D

Journal article

Controlling the excessive fracture burden in patients with chronic kidney disease (CKD) Stages G4–G5D remains an impressive challenge. The reasons are 2-fold. First, the pathophysiology of bone fragility in patients with CKD G4–G5D is complex and multifaceted, comprising a mixture of age-related (primary male/postmenopausal), drug-induced and CKD-related bone abnormalities. Second, our current armamentarium of osteoporosis medications has not been developed for, or adequately studied in patients with CKD G4–G5D, partly related to difficulties in diagnosing osteoporosis in this specific setting and fear of complications. Doubts about the optimal diagnostic and therapeutic approach fuel inertia in daily clinical practice. The scope of the present consensus paper is to review and update the assessment and diagnosis of osteoporosis in patients with CKD G4-G5D and to discuss the therapeutic interventions available and the manner in which these can be used to develop management strategies for the prevention of fragility fracture. As such, it aims to stimulate a cohesive approach to the management of osteoporosis in patients with CKD G4–G5D to replace current variations in care and treatment nihilism.

Authors: Evenepoel, P; Cunningham, J; Ferrari, S; Haarhaus, M; Javaid, MK

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Oxford University Press
• Journal: Nephrology Dialysis Transplantation
• Volume: 36
• Issue: 1
• Pages: 42–59
• Publication date: 2020-10-24
• Acceptance date: 2020-06-17
• DOI: 10.1093/ndt/gfaa192
• EISSN: 1460-2385
• ISSN: 0931-0509
• Language: English
• Keywords: renal osteodystrophy; bone mineral density; chronic renal insufficiency; CKD-MBD; FFR; mineral metabolism